1. Home
  2. FDMT
  3. FDMT News

Latest 4D Molecular Therapeutics Inc. (FDMT) News on May 9, 2025

FDMT

MT Newswires

5 hours ago

RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
FDMT

Zacks

20 hours ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
FDMT

GlobeNewswire

21 hours ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in Upcoming Investor Conferences
FDMT

GlobeNewswire

4 days ago

4DMT to Participate in Upcoming Investor Conferences

FDA awards RMAT status to 4DMT diabetic macular oedema therapy
FDMT

Pharmaceutical Technology

7 days ago

FDA awards RMAT status to 4DMT diabetic macular oedema therapy

FDMT

MT Newswires

8 days ago

4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
FDMT

GlobeNewswire

8 days ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Discover Fractyl Health And 2 More Promising Penny Stocks
FDMT

Simply Wall St.

17 days ago

Discover Fractyl Health And 2 More Promising Penny Stocks

4DMT Announces New Employment Inducement Grants
FDMT

GlobeNewswire

a month ago

4DMT Announces New Employment Inducement Grants

Biotech stocks slide as Marks resignation seen being negative for sector
FDMT

TipRanks

a month ago

Biotech stocks slide as Marks resignation seen being negative for sector

4DMT to Participate in Upcoming Investor Conferences
FDMT

GlobeNewswire

a month ago

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
FDMT

GlobeNewswire

2 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

4D Molecular price target lowered to $35 from $39 at RBC Capital
FDMT

TipRanks

2 months ago

4D Molecular price target lowered to $35 from $39 at RBC Capital

FDMT

MT Newswires

2 months ago

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating

FDMT

MT Newswires

2 months ago

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations
FDMT

Simply Wall St.

2 months ago

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
FDMT

GlobeNewswire

2 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Spotlight On February 2025's Promising Penny Stocks
FDMT

Simply Wall St.

2 months ago

Spotlight On February 2025's Promising Penny Stocks

4DMT to Participate in Upcoming Investor Conferences
FDMT

GlobeNewswire

3 months ago

4DMT to Participate in Upcoming Investor Conferences

FDMT

MT Newswires

3 months ago

Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
FDMT

GlobeNewswire

3 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
FDMT

GlobeNewswire

3 months ago

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

Top US Penny Stocks To Watch In January 2025
FDMT

Simply Wall St.

4 months ago

Top US Penny Stocks To Watch In January 2025

FDMT

MT Newswires

4 months ago

BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40

FDMT

MT Newswires

4 months ago

4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
FDMT

GlobeNewswire

4 months ago

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
FDMT

GlobeNewswire

4 months ago

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
FDMT

GlobeNewswire

5 months ago

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now
FDMT

Insider Monkey

5 months ago

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
FDMT

GlobeNewswire

6 months ago

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

FDMT

MT Newswires

6 months ago

RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
FDMT

Zacks

6 months ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
FDMT

GlobeNewswire

6 months ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
FDMT

Simply Wall St.

6 months ago

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
FDMT

Zacks

7 months ago

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FDMT

Zacks

7 months ago

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
FDMT

GlobeNewswire

8 months ago

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

FDMT

MT Newswires

8 months ago

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
FDMT

Benzinga

8 months ago

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
FDMT

BioPharma Dive

8 months ago

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

FDMT

MT Newswires

8 months ago

Chardan Lifts Price Target on 4D Molecular Therapeutics to $39 From $38, Keeps Buy Rating

FDMT

MT Newswires

8 months ago

4D Molecular Therapeutics Reveals 'Robust, Durable Clinical Activity' in Wet AMD Drug Trial

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
FDMT

GlobeNewswire

8 months ago

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4DMT Announces Presentations at Upcoming Retina Conferences
FDMT

GlobeNewswire

8 months ago

4DMT Announces Presentations at Upcoming Retina Conferences

4DMT to Participate in the 2024 Cantor Global Healthcare Conference
FDMT

GlobeNewswire

8 months ago

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
FDMT

GlobeNewswire

8 months ago

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
FDMT

Zacks

9 months ago

4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
FDMT

GlobeNewswire

9 months ago

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
FDMT

Simply Wall St.

9 months ago

4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
FDMT

Zacks

9 months ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
FDMT

GlobeNewswire

9 months ago

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
FDMT

GlobeNewswire

9 months ago

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

FDMT

MT Newswires

10 months ago

BMO Capital Cuts 4D Molecular Therapeutics Price Target to $40 From $63, Maintains Outperform Rating

FDMT

MT Newswires

10 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Wednesday

FDMT

MT Newswires

10 months ago

Sector Update: Health Care

FDMT

MT Newswires

10 months ago

4D Molecular Therapeutics' Phase 2 Trial Shows 4D-150 Therapy Effective in Treating Wet Age-Related Macular Degeneration

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
FDMT

GlobeNewswire

10 months ago

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

FDMT

MT Newswires

10 months ago

4d Molecular Therapeutics Insider Sold Shares Worth $290,598, According to a Recent SEC Filing

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
FDMT

Zacks

10 months ago

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?
FDMT

Insider Monkey

10 months ago

4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock?

FDMT

MT Newswires

a year ago

4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
FDMT

GlobeNewswire

a year ago

4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
FDMT

GlobeNewswire

a year ago

4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
FDMT

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
FDMT

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
FDMT

Business Wire

a year ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts
FDMT

AFP

a year ago

New Zealand scraps plan to tax livestock burps, farts

FDMT

Business Wire

a year ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
FDMT

The Wall Street Journal

a year ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool
FDMT

Bloomberg

a year ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024
FDMT

Simply Wall St.

a year ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
FDMT

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
FDMT

GlobeNewswire

a year ago

4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
FDMT

GlobeNewswire

a year ago

4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting

4DMT to Participate in Upcoming Investor Conferences
FDMT

GlobeNewswire

a year ago

4DMT to Participate in Upcoming Investor Conferences

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47áµ—Ê° European Cystic Fibrosis Conference
FDMT

GlobeNewswire

a year ago

4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47áµ—Ê° European Cystic Fibrosis Conference

We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
FDMT

Simply Wall St.

a year ago

We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow

4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)
FDMT

Simply Wall St.

a year ago

4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

FDMT

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
FDMT

GlobeNewswire

a year ago

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

4DMT to Participate in Upcoming Investor Conference
FDMT

GlobeNewswire

a year ago

4DMT to Participate in Upcoming Investor Conference

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
FDMT

Zacks

a year ago

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

4DMT Announces Presentations at ARVO 2024 Annual Meeting
FDMT

GlobeNewswire

a year ago

4DMT Announces Presentations at ARVO 2024 Annual Meeting

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
FDMT

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
FDMT

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
FDMT

GlobeNewswire

a year ago

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

4DMT to Participate in Upcoming Investor Conferences
FDMT

GlobeNewswire

a year ago

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
FDMT

Simply Wall St.

a year ago

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations
FDMT

Simply Wall St.

a year ago

4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations

FDMT

GuruFocus.com

a year ago

4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
FDMT

Zacks

a year ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

4DMT Reports Full Year 2023 Financial Results and Operational Highlights
FDMT

GlobeNewswire

a year ago

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
FDMT

Zacks

a year ago

Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposiumâ„¢ 2024
FDMT

GlobeNewswire

a year ago

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposiumâ„¢ 2024

Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
FDMT

Simply Wall St.

a year ago

Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth

Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc
FDMT

GuruFocus.com

a year ago

Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
FDMT

GlobeNewswire

a year ago

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
FDMT

GlobeNewswire

a year ago

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

FDMT

Reuters

a year ago

4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
FDMT

GlobeNewswire

a year ago

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

Share on Social Networks: